Weight LossMetabolicPrices may be stale · 1mo ago

Survodutide

Survodutide is an investigational dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim under a research collaboration with Zealand Pharma, which receives development and sales milestones, studied for obesity and metabolic liver disease. It holds FDA Breakthrough Therapy designation for MASH but is not approved.

Lowest cost / mg: $6.25/mg; at Peptide Labs Inc
Suppliers listed: 5
In stock: 4 of 8; listings
COA reports: 7

Jump to

Overview Supplier Listings Benefits Evidence Interactions FAQ

Supplier listings

Compare Survodutide prices.

Form

Show prices as

Size

8 listings · Survodutide

Peptide Labs IncLowest $/mg
In stock10 mg · 10 vialsseen 7w ago
$562.50
$625.00$5.63/mg-10%
PEPLOOKUP
Ares Research Lab
In stock5mgseen 7w ago
$55.24
$64.99$11.05/mg-15%
PRODUCTS
Biologix Labs
Out of stock10mgseen 5w ago
$61.19
$67.99$6.12/mg-10%
PEPLOOKUP
Alpha Peptides
Out of stock10mgseen 7w ago
$66.50
$73.89$6.65/mg-10%
peplookup
NextGen Peps
Out of stock10mgseen 7w ago
$78.30
$87.00$7.83/mg-10%
PEPLOOKUP

Overview

What is Survodutide?

Weight Management
Liver Health
Dual Mechanism
Metabolic Health

What the research reports

Reported benefits of Survodutide

Outcomes described across the published Survodutide literature and ongoing study. Read each as research context, not a promised result.

01
Dual mechanism weight effect
Combines GLP-1 appetite suppression with glucagon driven energy expenditure, which may offer an edge over GLP-1 only agents. Reported in research settings.
02
Weight loss in phase 2 work
Phase 2 work reported body weight reduction of 14.9 percent against 2.8 percent on placebo in adults with obesity. Noted across the published research record.
03
Liver disease study record
Phase 2 data reported resolution of metabolic liver disease without fibrosis progression in 62 percent against 14 percent on placebo. Reported in research settings.
04
Glycaemic improvement data
A phase 2 trial in type 2 diabetes reported HbA1c down up to 1.68 percent with 8.7 percent body weight reduction over 16 weeks. Reported in research settings.
05
Breakthrough therapy status
The FDA granted Breakthrough Therapy status for non-cirrhotic MASH with moderate or advanced fibrosis in September 2024. Reported in research settings.

Clinical evidence

Clinical evidence for Survodutide

The published record for Survodutide, labeled by strength so you can see what is settled and what is emerging.

Phase 2 diabetes dose study

A 2024 Diabetologia trial in 413 people with type 2 diabetes reported HbA1c down up to 1.68 percent and body weight down 8.7 percent across 16 weeks. Reported in the cited paper.

Source

SYNCHRONIZE phase 3 design

A 2025 Obesity paper set out the design of two phase 3 trials (SYNCHRONIZE-1 and -2), pre-specifying body weight reduction and the proportion achieving at least 5 percent loss as key endpoints. This paper describes the planned trial design, not reported results.

Source

Phase 2 subgroup analysis

A 2025 analysis of 387 participants reported reduced body weight and waist circumference with comparable safety across sex and baseline BMI subgroups. Reported in the cited paper.

Source

Interactions

How it pairs with other peptides

Semaglutide: Overlapping GLP-1 activity. No trial has tested the two agents together in the same protocol.
Mazdutide peptide: Both are glucagon and GLP-1 dual agonists, so combining duplicates the same two receptor targets.
Insulin therapy: The glucagon component raises hepatic glucose output, making glucose monitoring more important.
Sulfonylureas: Combined glucose lowering raises hypoglycaemia risk and needs clinical review before use. Confidence: emerging.

Questions

Frequently asked questions.

What is Survodutide?

Survodutide is an investigational dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim, studied for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH).

What are the research benefits of Survodutide?

Phase 2 and Phase 3 trials have reported significant body weight reduction (up to 14.9% at 46 weeks in the planned-treatment analysis), improvements in HbA1c in people with type 2 diabetes, and MASH resolution without worsening fibrosis in a majority of treated participants versus placebo.

How does Survodutide work?

It activates both the GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure, a dual mechanism distinct from GLP-1-only drugs like semaglutide.

Is Survodutide approved or for research use only?

Survodutide is not FDA-approved. It holds FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate or advanced fibrosis and remains in Phase 3 trials. Products listed on PepLookup are for laboratory and research use only; PepLookup does not provide dosing or administration guidance.

What should I look for before buying Survodutide?

Confirm third-party Certificate of Analysis (COA) results verifying identity and purity, check that the supplier is transparent about the compound's investigational, unapproved status, and compare documentation and pricing across the suppliers listed on this page.

Survodutide

Lowest cost / mg

$6.25/mg

at Peptide Labs Inc

Suppliers listed

In stock

4 of 8

listings

COA reports

What is Survodutide?

Weight Management

Liver Health

Dual Mechanism

Metabolic Health

Reported benefits of Survodutide

Outcomes described across the published Survodutide literature and ongoing study. Read each as research context, not a promised result.

Dual mechanism weight effect

Combines GLP-1 appetite suppression with glucagon driven energy expenditure, which may offer an edge over GLP-1 only agents. Reported in research settings.

Weight loss in phase 2 work

Phase 2 work reported body weight reduction of 14.9 percent against 2.8 percent on placebo in adults with obesity. Noted across the published research record.

Liver disease study record

Phase 2 data reported resolution of metabolic liver disease without fibrosis progression in 62 percent against 14 percent on placebo. Reported in research settings.

Glycaemic improvement data

A phase 2 trial in type 2 diabetes reported HbA1c down up to 1.68 percent with 8.7 percent body weight reduction over 16 weeks. Reported in research settings.

Breakthrough therapy status

The FDA granted Breakthrough Therapy status for non-cirrhotic MASH with moderate or advanced fibrosis in September 2024. Reported in research settings.

Clinical evidence for Survodutide

The published record for Survodutide, labeled by strength so you can see what is settled and what is emerging.

Phase 2 diabetes dose study

A 2024 Diabetologia trial in 413 people with type 2 diabetes reported HbA1c down up to 1.68 percent and body weight down 8.7 percent across 16 weeks. Reported in the cited paper.

Source

SYNCHRONIZE phase 3 design

Source

Phase 2 subgroup analysis

A 2025 analysis of 387 participants reported reduced body weight and waist circumference with comparable safety across sex and baseline BMI subgroups. Reported in the cited paper.

Source

How it pairs with other peptides

Semaglutide

Overlapping GLP-1 activity. No trial has tested the two agents together in the same protocol.

Mazdutide peptide

Both are glucagon and GLP-1 dual agonists, so combining duplicates the same two receptor targets.

Insulin therapy

The glucagon component raises hepatic glucose output, making glucose monitoring more important.

Sulfonylureas

Combined glucose lowering raises hypoglycaemia risk and needs clinical review before use. Confidence: emerging.